Armodafinil

Armodafinil (Nuvigil) is a stimulant-like drug produced by the pharmaceutical company Cephalon Inc., which was approved by the FDA on June 15, 2007. Armodafinil is the active (−)-(R)-enantiomer of the racemic drug modafinil (Provigil). Cephalon plans to conduct clinical trials evaluating the use of Nuvigil as a treatment for serious medical conditions such as bipolar depression, cognition abnormalities associated with schizophrenia, and excessive... more

Armodafinil (Nuvigil) is a stimulant-like drug produced by the pharmaceutical company Cephalon Inc., which was approved by the FDA on June 15, 2007. Armodafinil is the active (−)-(R)-enantiomer of the racemic drug modafinil (Provigil). Cephalon plans to conduct clinical trials evaluating the use of Nuvigil as a treatment for serious medical conditions such as bipolar depression, cognition abnormalities associated with schizophrenia, and excessive sleepiness, and fatigue in conditions such as Parkinson's disease, cancer, and narcolepsy, which is a sleep disorder. Nuvigil is protected by a U.S. patent expiring in 2023 that claims the Form 1 polymorph of armodafinil. Nuvigil is available for prescription as of June 1, 2009. less